InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Enochian Biosciences is a pre-clinical stage biotechnology company committed to us...
Enochian Biosciences is a pre-clinical stage bi...
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with ...
Co-Diagnostics, Inc., a Utah corporation, is a ...
Correvio has two marketed, in-hospital, cardiology products: BRINAVESSÂŽ (vernakal...
Correvio has two marketed, in-hospital, cardiol...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet...
Theratechnologies (TSX: TH) is a specialty phar...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
We are a clinical-stage biopharmaceutical company focused on the development of no...
We are a clinical-stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.